Related Experiment Video
Updated: Jun 5, 2025
06:34
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
Published on: November 29, 2024
188
Survodutide in MASH: bridging the gap between hepatic and systemic metabolic dysfunction.
Eda Kaya1,2, Yusuf Yilmaz2,3, Naim Alkhouri2,4
1Department of Medicine, Knappschaftskrankenhaus Bochum, Ruhr University, Bochum, Germany.
Expert Opinion on Investigational Drugs
|December 12, 2024
Summary
Survodutide, a dual glucagon receptor (GCGR) and GLP-1 receptor (GLP-1R) agonist, shows promise for treating obesity and metabolic dysfunction-associated steatohepatitis (MASH), potentially aiding fibrosis regression.
Area of Science:
- Pharmacology and clinical development of novel therapeutics for metabolic disorders.
Background:
- Glucagon-like peptide-1 receptor (GLP-1R) agonists effectively treat obesity and type 2 diabetes.
- Their role in resolving metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis is under investigation.
- Survodutide is an investigational dual agonist targeting both glucagon receptor (GCGR) and GLP-1R.
Purpose of the Study:
- To review the pharmacological profile, clinical efficacy, and safety of survodutide.
- To assess its potential in managing obesity and MASH.
Main Methods:
- Review of phase 1 and 2 clinical trial data for survodutide.
- Analysis of dual GCGR and GLP-1R agonism effects.
Main Results:
- Survodutide demonstrates potential for MASH resolution and fibrosis regression, possibly exceeding selective GLP-1R agonists.
- The drug is generally well-tolerated, with manageable gastrointestinal side effects.
Conclusions:
- Survodutide offers a promising therapeutic approach for MASH and related conditions.
- Further phase 3 trials are expected to confirm its efficacy and impact on patient outcomes.
Related Concept Videos
01:17Hepatic Drug Excretion: Enterohepatic Cycling
1.0K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.0K
01:14Drug Metabolism: Phase II Reactions
3.6K
Phase II reactions are essential for the detoxification and elimination of drugs from the body. These reactions involve the conjugation of parent drugs or their phase I metabolites with endogenous molecules, resulting in more hydrophilic drug conjugates. The primary conjugation reactions in this phase are sulfation and glucuronidation. Both sulfation and glucuronidation typically produce biologically inactive metabolites. However, in some cases involving prodrugs, active metabolites may be...
3.6K
01:16Drug Biotransformation: Overview
2.3K
Pharmaceutical substances known as xenobiotics are predominantly lipophilic and nonionized. This enables them to permeate lipid bilayers, such as cell membranes, and interact with intracellular target receptors. Lipophilic drugs have an advantage in crossing biological barriers and reaching their intended sites of action. However, lipophilic drugs often have a restricted capacity for renal expulsion or elimination from the body. When these drugs enter the kidneys and undergo glomerular...
2.3K
01:12First Pass Effect
5.1K
Presystemic elimination, or the first-pass effect, is the metabolism of drugs that reduces their effective concentration at the site of action. Apart from the first-pass effect, the systemic bioavailability of the drug is also reduced by other factors, including incomplete absorption or chemical degradation of drugs.
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
Depending on the route of administration, drugs can be metabolized in the liver, intestine, lungs, and vasculature. Orally administered drugs are first absorbed through the...
5.1K
01:24Factors Influencing Drug Absorption: Presystemic Elimination
176
The pharmacokinetic journey of oral drugs begins with a crucial first pass through the hepatic portal system, called the first-pass effect. This first pass significantly impacts bioavailability — the proportion of a drug that enters systemic circulation and is available for therapeutic action. The primary route sees the drug absorbed by intestinal membranes and then shunted to the liver via the hepatic portal vein. Here, pre-systemic elimination occurs as drugs face metabolism or biliary...
176
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
26
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
26